{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T02:40:33Z","timestamp":1789872033489,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Metab"],"DOI":"10.1038\/s42255-024-00973-5","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T06:02:53Z","timestamp":1707976973000},"page":"189-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Best practices in collecting and reporting continuous glucose monitoring data in research settings"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-4028","authenticated-orcid":false,"given":"Margaretha M.","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"973_CR1","unstructured":"European Medicines Agency. Clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus - scientific guideline. ema.europa.eu, https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-or-prevention-diabetes-mellitus-scientific-guideline (2023)."},{"key":"973_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino, T. et al. Lancet Diabetes Endocrinol 11, 42\u201357 (2023).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"973_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2337\/dc17-1600","volume":"40","author":"T Danne","year":"2017","unstructured":"Danne, T. et al. Diabetes Care 40, 1631\u20131640 (2017).","journal-title":"Diabetes Care"},{"key":"973_CR4","doi-asserted-by":"publisher","first-page":"e0216851","DOI":"10.1371\/journal.pone.0216851","volume":"14","author":"T Vigers","year":"2019","unstructured":"Vigers, T. et al. PLoS ONE 14, e0216851 (2019).","journal-title":"PLoS ONE"},{"key":"973_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/dia.2017.0455","volume":"20","author":"TD Riddlesworth","year":"2018","unstructured":"Riddlesworth, T. D. et al. Diabetes Technol. Ther. 20, 314\u2013316 (2018).","journal-title":"Diabetes Technol. Ther."},{"key":"973_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino, T. et al. Diabetes Care 42, 1593\u20131603 (2019).","journal-title":"Diabetes Care"},{"key":"973_CR7","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","volume":"64","author":"RIG Holt","year":"2021","unstructured":"Holt, R. I. G. et al. Diabetologia 64, 2609\u20132652 (2021).","journal-title":"Diabetologia"},{"key":"973_CR8","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1089\/dia.2021.0007","volume":"23","author":"MA Jackson","year":"2021","unstructured":"Jackson, M. A., Ahmann, A. & Shah, V. N. Diabetes Technol. Ther. 23, S27\u2013S34 (2021).","journal-title":"Diabetes Technol. Ther."},{"key":"973_CR9","unstructured":"Food and Drug Administration, Center for Drug Evaluation and Research. Diabetes mellitus: efficacy endpoints for clinical trials investigating antidiabetic drugs and biological products; draft guidance for industry. regulations.gov, https:\/\/www.regulations.gov\/docket\/FDA-2023-D-0625 (2023)."},{"key":"973_CR10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/19322968211069177","volume":"17","author":"SL Cichosz","year":"2023","unstructured":"Cichosz, S. L., Jensen, M. H. & Hejlesen, O. J. Diabetes Sci. Technol. 17, 690\u2013695 (2023).","journal-title":"J. Diabetes Sci. Technol."},{"key":"973_CR11","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.2337\/dc21-2298","volume":"45","author":"JM Lachin","year":"2022","unstructured":"Lachin, J. M., Bebu, I., Gao, X., Nathan, D. M. & Zinman, B. Diabetes Care 45, 2445\u20132448 (2022).","journal-title":"Diabetes Care"},{"key":"973_CR12","doi-asserted-by":"publisher","first-page":"e14892","DOI":"10.1111\/dme.14892","volume":"39","author":"P Divilly","year":"2022","unstructured":"Divilly, P. et al. Diabet. Med. 39, e14892 (2022).","journal-title":"Diabet. Med."},{"key":"973_CR13","doi-asserted-by":"publisher","first-page":"100853","DOI":"10.1016\/j.eclinm.2021.100853","volume":"35","author":"S Barua","year":"2021","unstructured":"Barua, S. et al. EClinicalMedicine 35, 100853 (2021).","journal-title":"EClinicalMedicine"},{"key":"973_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1177\/1932296820965599","volume":"16","author":"S Sofizadeh","year":"2022","unstructured":"Sofizadeh, S., Pehrsson, A., \u00d3lafsd\u00f3ttir, A. F. & Lind, M. J. Diabetes Sci. Technol. 16, 373\u2013382 (2022).","journal-title":"J. Diabetes Sci. Technol."},{"key":"973_CR15","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1177\/1932296818774078","volume":"12","author":"M Vettoretti","year":"2018","unstructured":"Vettoretti, M., Cappon, G., Acciaroli, G., Facchinetti, A. & Sparacino, G. J. Diabetes Sci. Technol. 12, 1064\u20131071 (2018).","journal-title":"J. Diabetes Sci. Technol."}],"container-title":["Nature Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-00973-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-00973-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T19:04:57Z","timestamp":1708974297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42255-024-00973-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1038\/s42255-024-00973-5","relation":{},"ISSN":["2522-5812"],"issn-type":[{"value":"2522-5812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]},"assertion":[{"value":"15 February 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UZ Leuven received non-financial support for travel from Novo Nordisk, and Boehringer-Ingelheim for M.M.V. M.M.V. serves or has served on the speakers bureau for Dexcom \u2014 financial compensation for these activities has been received by KU Leuven. P.G. serves or has served on the advisory panel for Novo Nordisk, Sanofi-Aventis, Boehringer-Ingelheim, Janssen Pharmaceuticals, Roche, Medtronic, Abbott and Bayer. Financial compensation for these activities has been received by KU Leuven. P.G. serves or has served on the speakers bureau for Merck Sharp and Dohme, Boehringer-Ingelheim, Bayer, Medtronic, Insulet, Novo Nordisk, Abbott, Roche, VitalAire and Dexcom. Financial compensation for these activities has been received by KU Leuven. KU Leuven received for P.G. non-financial support for travel from Sanofi-Aventis, A. Menarini Diagnostics, Novo Nordisk, Medtronic, and Roche. All disclosures were unrelated to the present work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}